Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma

Blood Cancer Discov. 2021 Jul;2(4):297-299. doi: 10.1158/2643-3230.BCD-21-0073.


BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T-cell redirecting immunotherapy to treat relapsed and refractory multiple myeloma (MM). However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic MM model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T-cells, and is superior to pomalidomide or bortezomib in enhancing durable anti-MM efficacy.

Keywords: BCMA; Bispecific antibody; Cyclophosphamide; Immunotherapy; Multiple Myeloma.